Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714864 | 0.87 | CRHR1 (0.47) | CRHR1HPGDMAPTALDH1A1GAA | |
| SCHEMBL5739946 | 0.81 | CRHR1 (0.47) | CRHR1TNKSHPGDKDM4EMAPK1 | |
| SCHEMBL5739590 | 0.79 | ADORA2A (0.45) | HPGDKDM4EMAPK1ALDH1A1GAA | |
| SCHEMBL5738740 | 0.79 | CHEK1 (0.41) | GUSBALDH1A1 | |
| SCHEMBL5738676 | 0.78 | IDO1 (0.52) | HPGDMAPTKDM4EALDH1A1 | |
| SCHEMBL5739673 | 0.78 | KDM4E (0.45) | MAPTKDM4EMAPK1ALDH1A1GAA | |
| SCHEMBL5738472 | 0.77 | ADORA1 (0.36) | ALDH1A1 | |
| SCHEMBL5738829 | 0.77 | DHODH (0.39) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL5739520 | 0.76 | DCUN1D1 (0.40) | HPGDMAPTKDM4EMAPK1ALDH1A1 | |
| SCHEMBL5248567 | 0.76 | KMT2A (0.44) | GUSBHPGDMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | claimed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | CRHR1 3365/4885DPP4 4115/4885GUSB 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.